bearish
Glenmark Pharmaceuticals: Attempt Out of Generic
431 Views12 Oct 2018 09:26
We initiate our coverage on Glenmark Pharmaceuticals (GNP IN) (“Glenmark”)’s GNPIN 4.5% 8/21s (BB-/BB by S&P and Fitch, respectively) with a...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 20-minute read)
Discussions
(Paid Plans Only)
Bondcritic
Asian Fixed Income/Frontier Market Research
Price Chart(Sign Up to Access)
- Parkway Pantai: Good Brand with Limited Upside03 Aug 2020
- Jubilant Pharma: Good Drugs, Fully-Valued Bonds26 Jun 2020
- Thomson Medical Group: Medicated by Leverage22 May 2020
- Para IV Winners and Losers - June 201810 Jul 2018
- Delhi International Airport: At a Steady Altitude24 May 2018
- Lupin Ltd.: Another Undervalued Generic Drugs Powerhouse17 Nov 2016
x